Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07218471

Cannabis Reduction and Functional Outcomes

This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cannabis Use Disorder

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18+
  • Urinary cannabinoid level ≥ 50 ng/mL
  • DSM-5 diagnosis of CUD (mild, moderate, or severe)
  • Willingness to attempt cannabis reduction
  • Completion of Intake Visit

Exclusion criteria

  • Serious medical/psychiatric conditions
  • Pregnancy or breastfeeding
  • Use of cannabis in past 30 days was for medical purposes only
  • Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
  • Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz

Treatment and study plan

CBT4CBT (Computerized Cognitive Behavioral Therapy)

Behavioral

Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

Motivational Interviewing

Behavioral

Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

Contingency Management

Behavioral

Patients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids).

Primary outcomes

  1. Cannabis-Related Problems

    Time frame: Week 8 (end-of-treatment)

    Rutgers Marijuana Problem Index (RMPI)- higher scores associated with worse outcomes.

Secondary outcomes

  1. Total minutes of sleep per night

    Time frame: Week 8 (end-of-treatment)

    Measured via Fitbit Charge.

  2. Minutes of light sleep per night

    Time frame: Week 8 (end-of-treatment)

    Measured via Fitbit Charge.

  3. Minutes of rapid eye movement (REM) sleep per night

    Time frame: Week 8 (end-of-treatment)

    Measured via Fitbit Charge.

  4. Minutes of deep sleep per night

    Time frame: Week 8 (end-of-treatment)

    Measured via Fitbit Charge.

  5. Sleep efficiency rating

    Time frame: Week 8 (end-of-treatment)

    "Sleep score" as provided by Fitbit Charge. Range is 1-100 with higher scores indicating better sleep quality/efficiency.

  6. Rey Auditory Verbal Learning Test (Verbal Memory) Age-Adjusted Standard Score

    Time frame: Week 8 (end-of-treatment)

    NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.

  7. Face/Name Associative Memory Test (Visual Memory) Age-Adjusted Standard Score

    Time frame: Week 8 (end-of-treatment)

    NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.

  8. Oral Symbol Digit Test Age-Adjusted Standard Score

    Time frame: Week 8 (end-of-treatment)

    NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.

  9. Pattern Comparison Processing Speed Test (Processing Speed) Age-Adjusted Standard Score

    Time frame: Week 8 (end-of-treatment)

    NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.

Other outcomes

  1. DSM-5 CUD Criteria and Severity

    Time frame: Week 8 (end-of-treatment)

    Clinician-administered semi-structured interview for assessing past month DSM-5 CUD symptoms

  2. Quality of Life Enjoyment and Satisfaction-Q-SF

    Time frame: Week 8 (end-of-treatment)

    Self-report measure- range is 0-100% and higher percentages are associated with better outcomes

Study contacts

Contact information is provided by the study sponsor or research team.

Erin McClure, PhD

CONTACT

[email protected]

(843) 792-7192

Rachel Tomko, PhD

CONTACT

[email protected]

(843) 792-5447

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • National Institutes of Health (NIH)

Registry information

Official study title

Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Oct 20, 2025
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.